BLOCKING THE INHIBITORY CD94/NKG2A NK CELL RECEPTOR WITH A NOVEL ANTI-NKG2A MAB ENHANCES THE SUSCEPTIBILITY OF RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES (FLS) TO NK CELL-MEDIATED CYTOTOXICITY

BLOCKING THE INHIBITORY CD94/NKG2A NK CELL RECEPTOR WITH A NOVEL ANTI-NKG2A MAB ENHANCES THE SUSCEPTIBILITY OF RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES (FLS) TO NK CELL-MEDIATED CYTOTOXICITY

Detalles Bibliográficos
Autores principales:	Nielsen, N, Galsgaard, E, Ahern, D, Andersen, M, Spee, P, Feldmann, M, Brennan, F, Soederstroem, K
Formato:	Journal article
Publicado:	2012

Ejemplares similares

HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells.
por: King, A, et al.
Publicado: (2000)

The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
por: Meike Kaulfuss, et al.
Publicado: (2023-06-01)

Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts.
por: Nielsen, N, et al.
Publicado: (2014)

CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors
por: Chiara Giordano, et al.
Publicado: (2025-01-01)

Inhibitory NKG2A+ and absent activating NKG2C+ NK cell responses are associated with the development of EBV+ lymphomas
por: Hannes Vietzen, et al.
Publicado: (2023-06-01)

Dissection of the NKG2C NK cell response against Puumala Orthohantavirus.
por: Hannes Vietzen, et al.
Publicado: (2021-12-01)

Responsiveness to Influenza Vaccination Correlates with NKG2C-Expression on NK Cells
por: Peggy Riese, et al.
Publicado: (2020-06-01)

Polyclonal Expansion of NKG2C+ NK Cells in TAP-deficient Patients
por: vivien eBeziat, et al.
Publicado: (2015-10-01)

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
por: Christine Koch, et al.
Publicado: (2017-11-01)

CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA-G by decidual and peripheral blood NK cells.
por: Söderström, K, et al.
Publicado: (1997)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Patrick Schlegel, et al.
Publicado: (2015-01-01)

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
por: Ignacio Melero, et al.
Publicado: (2023-10-01)

Activating KIRs and NKG2C in viral infections: towards NK cell memory?
por: Mariella eDella Chiesa, et al.
Publicado: (2015-11-01)

Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
por: Thornton W Thompson, et al.
Publicado: (2017-12-01)

Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E.
por: Braud, V, et al.
Publicado: (1999)

Improvement of NK Cell Cytotoxicity in Reconstituting NK Cells after Allogeneic Stem Cell Transplantation by Blocking NKG2A Checkpoint
por: Mohammed Taha, et al.
Publicado: (2023-10-01)

Increased proliferative response of highly differentiated CD57<sup>+</sup>NKG2C<sup>+</sup>NK cells expressing NKG2A
por: N. A. Alekseeva, et al.
Publicado: (2024-09-01)

Elusive Role of the CD94/NKG2C NK Cell Receptor in the Response to Cytomegalovirus: Novel Experimental Observations in a Reporter Cell System
por: Aldi Pupuleku, et al.
Publicado: (2017-10-01)

Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy
por: Peng Peng, et al.
Publicado: (2022-12-01)

Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease
por: Daniel Fernández-Soto, et al.
Publicado: (2024-02-01)

High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation
por: Huisman, BD, et al.
Publicado: (2023)

High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation
por: Brooke D. Huisman, et al.
Publicado: (2023-08-01)

POTENTIAL USAGE OF NK CELLS AND NKG2D-POSITIVE LYMPHOCYTES AS TARGETS IN THERAPY OF CROHN’S DISEASE
por: E. A. Shulenina, et al.
Publicado: (2017-08-01)

Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment
por: Raj Kumar, et al.
Publicado: (2024-08-01)

Pseudorabies Virus Infection Causes Downregulation of Ligands for the Activating NK Cell Receptor NKG2D
por: Sofie Denaeghel, et al.
Publicado: (2021-02-01)

Autophagy-mediated NKG2D internalization impairs NK cell function and exacerbates radiation pneumonitis
por: Ruiqing Wang, et al.
Publicado: (2023-11-01)

Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells
por: Stefanie Maurer, et al.
Publicado: (2018-02-01)

Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
por: Stephen Weber, et al.
Publicado: (2024-02-01)

Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
por: Zhuanyun Du, et al.
Publicado: (2022-06-01)

Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
por: Yan Zhang, et al.
Publicado: (2024-01-01)

Human Metapneumovirus Escapes NK Cell Recognition through the Downregulation of Stress-Induced Ligands for NKG2D
por: Mohammad Diab, et al.
Publicado: (2020-07-01)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Brwa Ali Hussein, et al.
Publicado: (2023-08-01)

Role of NKG2D-Expressing NK Cells and sMICA in Immune Surveillance of Advanced Lung Cancer
por: Jing LIANG, et al.
Publicado: (2009-01-01)

Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques.
por: Daniel R Ram, et al.
Publicado: (2018-05-01)

Publisher Correction: High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation
por: Brooke D. Huisman, et al.
Publicado: (2023-08-01)

Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D
por: Carina Gröschel, et al.
Publicado: (2017-07-01)

Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1.
por: Zhixia Zhou, et al.
Publicado: (2012-01-01)

502 Discovery of HX017, a novel NKG2A/CD94 mAb, for potential cancer immunotherapy
por: Faming Zhang, et al.
Publicado: (2023-11-01)

Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy
por: Yan Li, et al.
Publicado: (2024-10-01)

Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality
por: Raghad Khaleafi, et al.
Publicado: (2023-09-01)